KITLG and glioblastoma: These results suggest that the measurement of the SCF plasma level can aid in GBM patient's management for diagnostic purposes and as an efficient diagnostic plasma biomarker in patients with a new brain mass to differentiate between glioblastoma and nonglial tumors.